PainReform Ltd. (NASDAQ:PRFX) Sees Large Growth in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant increase in short interest in May. As of May 29th, there was short interest totaling 313,070 shares, an increase of 324.9% from the May 14th total of 73,684 shares. Currently, 54.9% of the company’s stock are short sold. Based on an average trading volume of 8,718,443 shares, the short-interest ratio is presently 0.0 days.

PainReform Trading Down 8.1%

Shares of PRFX stock traded down $0.12 on Friday, reaching $1.36. 132,939 shares of the stock were exchanged, compared to its average volume of 1,342,238. The business’s 50 day moving average price is $2.00 and its 200 day moving average price is $3.05. The company has a market capitalization of $1.18 million, a price-to-earnings ratio of 0.00 and a beta of 0.98. PainReform has a twelve month low of $1.28 and a twelve month high of $17.95.

PainReform (NASDAQ:PRFX) last issued its earnings results on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.